Acetylsalicylsäure – von der kardiovaskulären zur Karzinomprävention

Zusammenfassung

Kardiovaskuläre Erkrankungen und Tumorerkrankungen stellen nach wie vor weltweit die führenden Ursachen für Morbidität und Mortalität dar [1]. Durch die niedrig dosierte Gabe von ASS bei Patienten mit okklusiven kardiovaskulären Erkrankungen wie Koronare Herzerkrankung (KHK), periphere arterielle Verschlusskrankheit (pAVK) oder Schlaganfall, können ca. 20 % der thrombotischen vaskulären Komplikationen verhindert werden [2]. Insbesondere in der kardiovaskulären Sekundärprävention zeigt sich ein günstiges Nutzen-Risikoprofil einer ASS-Dauermedikation. Inwiefern ASS auch in der Primärprävention kardiovaskulärer Erkrankungen indiziert ist, wird derzeit noch kontrovers diskutiert. Ziel dieser Arbeit ist es, eine aktuelle Übersicht über die Evidenz einer niedrig dosierten ASS-Therapie in der Primär- und Sekundärprävention kardiovaskulärer Erkrankungen zu geben und darüber hinaus den möglichen zusätzlichen Nutzen einer ASS-Therapie in der Prävention von Tumoren zu diskutieren

Abstract

Cardiovascular disease and cancer are the leading causes of morbidity and mortality worldwide. Low-dose ASA has been shown to effectively prevent about one fifth of atherothrombotic vascular complications in patients with previous myocardial infarction, peripheral arterial occlusive disease (PAOD), or stroke [2]. In secondary prevention, the benefits of antiplatelet therapy substantially exceed its risk [2]. By contrast, recommendations for the use of ASA in primary prevention are still a matter of controversy. The aim of this article is to review the current evidence for the efficacy of low-dose ASA in primary and secondary prevention of cardiovascular diseases as well as to discuss its potential additional chemopreventive action.

Schlüsselwörter

kardiovaskuläre Prävention - Chemoprävention - ASS - Aspirin

Keywords

cardiovascular prevention - chemoprevention - ASS - aspirin

^* Veronika Sanin und Vanessa Pfetsch teilen sich die Erstautorenschaft.

• Literatur

• 1 WHO. Cardiovascular diseases (CVDs). Fact sheet No 317. www.who.int/mediacentre/factsheets/fs317/en/ Letzter Zugriff: 19.01.2016
• 2 Patrono C. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?. Eur Heart J 2013; 34: 3403-3411
• 3 Patrono C. The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol 2015; 66: 74-85
• 4 Fischbach W, Darius M, Gross M et al. Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonenpumpeninhibitoren (PPIs). Positionspapier der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Kardiologie (DGK). Z Gastroenterol 2010; 48: 1156-1163
• 5 Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121: 43-49
• 6 Patrono C, García Rodríguez LA, Landolfi R et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383
• 7 Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
• 8 Seshasai SR, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-216
• 9 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
• 10 Huang ES, Strate LL, Ho WW et al. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011; 124: 426-433
• 11 Ridker PM, Cook NR, Lee IM. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304
• 12 Berger JS, Roncaglioni MC, Avanzini F et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-313
• 13 Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55: 2878-2886
• 14 Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694-2701
• 15 Buse JB, Bigger JT, Byington RP. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: 21i-33i
• 16 Colwell JA, Halushka PV, Sarji K et al. Altered platelet function in diabetes mellitus. Diabetes 1976; 25: 826-831
• 17 De Berardis G, Sacco M, Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531
• 18 Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 405-410
• 19 Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 2008; 5: 138-144
• 20 Vandvik PO, Lincoff AM, Gore JM et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; e637S-68S
• 21 Patrono C, Andreotti F, Arnesen H et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932
• 22 Perk J, De Backer G, Gohlke H et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701
• 23 Stegeman I, Bossuyt PM, Yu T et al. Aspirin for primary prevention of cardiovascular disease and cancer. A benefit and harm analysis. PLoS one 2015; 10: e0127194
• 24 Rothwell PM, Price JF, Fowkes FG et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-1612
• 25 Cole BF, Logan RF, Halabi S et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-266
• 26 Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41
• 27 Cuzick J, Thorat MA, Bosetti C et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015; 26: 47-57
• 28 Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613
• 29 Jacobs EJ, Thun MJ, Bain EB et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-615
• 30 Fraser DM, Sullivan FM, Thompson AM et al. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer 2014; 111: 623-627
• 31 Trabert B, Ness RB, Lo-Ciganic WH et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 2014; 106: djt431
• 32 Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst, 2002; 94: 252-266
• 33 Sahin IH, Garrett C. Aspirin, PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2013; 368: 289
• 34 Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566-4569
• 35 Patrono C. Measurement of cyclooxygenase isozyme inhibition in humans: exploring the clinical relevance of biochemical selectivity. Clin Exp Rheumatol 2001; 19: S45-50
• 36 Ruffin 4th MT, Krishnan K, Rock CL et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 1997; 89: 1152-1160
• 37 Opie LH, Lopaschuk GD. What is good for the circulation also lessens cancer risk. Eur Heart J 2015; 36: 1157-1162
• 38 Errico A. Prevention: Daily aspirin and chemoprevention. Nat Rev Clin Oncol 2014; 11 (4) 180-180
• 39 Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 9: 259-267
• 40 Andreotti HalvorsenS, ten Berg JM et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 2014; 64: 319-327
• 41 Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 235-246
• 42 US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404
• 43 Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline „Helicobacter pylori and gastroduodenal ulcer disease“ of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009; 47: 1230-1263
• 44 Yeomans N, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103: 2465-2473
• 45 Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ et al. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. J Cardiovasc Pharmacol 2013; 61: 250-257
• 46 US Preventive Services Task Force. Draft recommendation statement: Aspirin to prevent cardiovascular disease and cancer. http://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/aspirin-to-prevent-cardiovascular-disease-and-cancer Letzter Zugriff: 04.02.2016